Clinical trial Recruiting at 1 site Observational

Measuring phosphorylated tau‑217 (pTau217) in donated blood plasma

Official title: Detection of Elevated Plasma pTau217 in Donated Human Blood Samples: Implications for Blood Transfusion Safety

Run by The University of Texas Health Science Center, Houston · NCT07157839 · Data updated 2026-11-12

This project will test donated blood plasma to see if some units contain high levels of phosphorylated tau‑217, a marker linked to Alzheimer's disease.

More s Disease trials

Quick facts

Study typeObservational
SexAll
Enrollment250 (estimated)
SponsorThe University of Texas Health Science Center, Houston
Academic / other
Locations1 site (Houston, Texas)
StatusRecruiting
StartedAugust 28, 2025
Main results expectedNovember 1, 2026
Study endsNovember 1, 2026
Registry record updatedFebruary 11, 2026
Trial IDNCT07157839 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal samples are plasma units donated through blood banks, supplemented by control plasma from people with clinically diagnosed Alzheimer's disease and healthy control participants.

Probably not a fit

Because this is a lab-based observational analysis of stored plasma samples, individual donors or recipients are unlikely to receive direct clinical benefit from participation.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational, laboratory-based study will measure pTau217 concentrations in about 250 donated plasma samples collected through a blood bank, including purchased samples from clinically diagnosed Alzheimer's patients and healthy controls. Measurements will use a nanoneedle biosensor or equivalent immunoassays and will compare pTau217 concentrations to total tau. The design is cross-sectional and prospective, with aliquots retained for potential further analysis. The main goals are to determine how often donated plasma shows elevated pTau217 and to generate preliminary data relevant to transfusion safety.

Why it matters

Potential benefit: If results show some donated plasma has high pTau217, they could inform screening practices to reduce potential Alzheimer's-related risks from transfusions.

How similar studies have gone: Prior research has shown blood pTau217 is a sensitive and specific biomarker for Alzheimer's disease, but applying pTau217 measurement to general blood donations and transfusion safety is a novel application.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* The plasma sample from donators.

Exclusion Criteria:

* None.

Where it's running

  • University of Texas Health Science Center at Houston
    Houston, Texas, United States
    Recruiting

Study contacts

  • Principal investigator: Zhongcong Xie, M.D., Ph.D. — The University of Texas Health Science Center, Houston
  • Study coordinator: Zhongcong Xie, M.D., Ph.D.
  • Email: Zhongcong.Xie@uth.tmc.edu
  • Phone: 17135006207

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.